Sign In
6 May 2021 07:00
Value Creation Plan Award
Oxford, U.K. 6 May 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the UK Clinical AI company, today reports that following the establishment in September 2020 of its value creation plan ("VCP") an allocation of unit awards has been made to the Company's Executive Directors, PDMRs and other eligible employees.
The grant of plan units to the Executive Directors are summarised in the table below:
Name | Title | Plan Units Awarded | % of Total Plan Units |
Lord Paul Drayson | Chief Executive Officer | 25,000 | 25% |
Dr Richard Pye | Chief Financial Officer | 8,000 | 8% |
A further 46,000 plan units, representing 46% of the total plan units, have been allocated to other eligible employees with notifications from persons discharging managerial responsibilities appended to this release. A total of 21% of the total plan units is currently reserved for future allocation. The VCP is represented by a total of 100,000 plan units with participants permitted to share a pool of value created from the growth in value of Sensyne share capital after a five-year period ending 23 July 2025.
The participation in the VCP by Lord Drayson and Dr Pye are considered to be related party transactions under the AIM Rules for Companies. The non-executive directors, having consulted with Peel Hunt as the Company's nominated adviser, consider Lord Drayson's and Dr Pye's participation in the VCP and the potential rewards to be fair and reasonable in so far as shareholders are concerned.
The below notifications, made in accordance with Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, gives further detail of the number of plan units awarded under the VCP.
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||
a. | Name | 1. Lord (Paul) Drayson 2. Dr Richard Pye 3. Michael Macdonnell 4. Laura Hillier 5. Dr Nick Scott-Ram | ||||||||||||
2. | Reason for the notification | |||||||||||||
a. | Position/status | 1. Chief Executive Officer 2. Chief Financial Officer 3. Chief Operating Officer 4. General Counsel and Company Secretary 5. Managing Director - Discovery Sciences | ||||||||||||
b. | Initial notification /Amendment | Initial | ||||||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor | |||||||||||||
a. | Name | Sensyne Health plc | ||||||||||||
b. | LEI | 213800A5BKO4A9OVO675 | ||||||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
a. | Description of the Financial instrument, type of instrument Identification code | Ordinary Shares of 10p each
GB00BYV3J755 | ||||||||||||
b. | Nature of the transaction | Grant of Plan Units, subject to the rules of the VCP, to receive a share in a pool of value created from the growth in value of Sensyne share capital after a five-year period ending 23 July 2025. The share of value is represented by units with the total value pool equalling 100,000 units. | ||||||||||||
c. | Price(s) and volume(s) |
| ||||||||||||
d. | Aggregated information - Aggregated volume - Price
|
N/A
| ||||||||||||
e. | Date of the transaction | 30 April 2021 | ||||||||||||
f. | Place of the transaction | Outside a regulated market | ||||||||||||
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson PhD FREng, Chief Executive Officer | |
Dr Richard Pye, Chief Financial Officer
| |
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+ 44 (0) 20 7418 8900 |
Dr Christopher Golden | |
James Steel | |
Victoria Erskine | |
Liberum (Joint Broker) | + 44 (0) 20 3100 2000 |
Bidhi Bhoma | |
Euan Brown | |
Consilium Strategic Communications | +44 (0) 20 3709 5700 |
Mary-Jane Elliott | |
Jessica Hodgson | |
Davide Salvi |
About Sensyne Health:
Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organizations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L). For more information visit www.sensynehealth.com.
Follow the stocks
